淋巴结阴性胰腺癌患者胰腺切除术后辅助化疗的效果:目标试验模拟
该观察性队列研究采用克隆-删失-加权方法模拟假想随机对照试验,纳入丹麦2008–2021年接受治愈性意向手术的胰腺癌患者(pN0 424例,pN+ 953例)。pN0患者接受与未接受辅助化疗的2年生存率差异为-2.2%(95%CI -11.8至7.4),pN+患者差异为9.9%(95%CI 1.6至18.1)。结论认为在淋巴结阴性胰腺癌中辅助化疗未改善术后生存。
要点
- pN0患者辅助化疗与未辅助化疗的2年生存率差异为-2.2%(95%CI -11.8至7.4)。
- pN+患者辅助化疗与未辅助化疗的2年生存率差异为9.9%(95%CI 1.6至18.1)。
- 接受与未接受辅助化疗患者的中位总生存分别为24.9个月和15.0个月。
核心结论
- 在采用观察性数据的目标试验模拟中,辅助化疗未改善淋巴结阴性胰腺癌术后生存。
研究设计与样本
- 观察性队列研究,采用克隆-删失-加权方法模拟假想随机对照试验,使用丹麦基于人群的医疗登记数据。
- 纳入2008–2021年接受治愈性意向手术的丹麦胰腺癌患者,术后出院存活且出院时间不超过术后4周,共pN0 424例和pN+ 953例。
- 在术后出院时复制每例患者数据,一份分配至辅助化疗策略,另一份分配至无辅助化疗策略,当分配治疗与观察治疗不兼容时删失,并对未删失患者按测得的混杂因素加权。
主要发现
- pN0患者中,62.0%在8周宽限期内开始辅助化疗;pN+患者中,74.6%在8周宽限期内开始辅助化疗。
- pN0患者接受与未接受辅助化疗的2年生存率差异为-2.2%(95%CI -11.8至7.4)%。
- pN+患者接受与未接受辅助化疗的2年生存率差异为9.9%(95%CI 1.6至18.1)%。
- 接受与未接受辅助化疗患者的中位总生存分别为24.9个月(四分位距12.8–49.4)和15.0个月(四分位距8.0–34.0)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effect of adjuvant therapy in node-negative pancreatic cancer is uncertain. The aim of this study was to estimate the effect of adjuvant chemotherapy on survival after surgery for pancreatic cancer in patients with node-negative (pN0) and node-positive (pN+) disease using target trial emulation. METHODS: This was an observational cohort study emulating a hypothetical RCT by the clone-censor-weight approach using population-based Danish healthcare registries. The study included Danish patients undergoing curative-intent surgery for pancreatic cancer during 2008-2021, who were discharged alive no more than 4 weeks after surgery. At the time of discharge after surgery, the data for each patient were duplicated; one copy was assigned to the adjuvant chemotherapy strategy and the other to the no adjuvant chemotherapy strategy of the hypothetical trial. Copies were censored when the assigned treatment was no longer compatible with the observed treatment. To account for informative censoring, uncensored patients were weighted according to measured confounders. The primary outcomes were absolute difference in 2-year survival and median overall survival, comparing adjuvant with no adjuvant chemotherapy. RESULTS: Some 424 patients with pN0 and 953 with pN+ disease were included. Of these, 62.0 and 74.6% respectively initiated adjuvant chemotherapy within the 8-week grace period. Among patients with pN0 tumours, the difference in 2-year survival between those with and without adjuvant therapy was -2.2 (95% c.i. -11.8 to 7.4)%. In those with pN+ disease, the difference in 2-year survival was 9.9 (1.6 to 18.1)%. Median overall survival was 24.9 (i.q.r. 12.8-49.4) and 15.0 (8.0-34.0) months for patients having adjuvant and no adjuvant therapy respectively. CONCLUSION: In a target trial emulation using observational data, adjuvant chemotherapy did not improve survival after surgery for node-negative pancreatic cancer.
引用
- Kirkegård J, Ladekarl M, Johannsen IR, et al. Effect of adjuvant chemotherapy after pancreatectomy in patients with node-negative pancreatic cancer: target trial emulation. Br J Surg. 2024. PMID: 38006324. doi:10.1093/bjs/znad398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。